The global spinal cord trauma market is set to grow at a 3.7 percent compound annual growth rate through 2025, according to a Market Research Reports Search Engine analysis.
Here are five observations:
1. Nerve cell growth therapy will serve as a driver for the global market.
2. The partial spinal cord injury sector will likely grow at a higher rate than the complete SCI segment.
3. Hospitals accounted for a 53.2 percent market share in 2017, but will likely drop to 52.5 percent by 2025.
4. Road accidents and crime will drive spinal cord trauma treatment market in the Asia-Pacific area.
5. Bioaxone Biosciences, Acorda Therapeutics, Kringle Pharma, Pfizer, Novartis, Vertex Pharmaceuticals, InVivo Therapeutics, BioArctic, Asterias Biotherapeutics, Pharmicell, ReNetX Bio and BioTime will lead the market.